POCIMEDIUM SIGNALOPERATIONAL10-K

POCI has strategically repositioned itself from a primarily medical device manufacturer to a dual-market company serving both medical devices and defense/aerospace sectors.

The company appears to be diversifying its revenue base by expanding into defense/aerospace markets, particularly satellite network communications, which could reduce dependence on medical device customers. However, the business expansion comes amid deteriorating financial performance, suggesting execution challenges during this strategic transition.

Comparing 2025-09-29 vs 2024-09-30View on EDGAR →
FINANCIAL ANALYSIS

POCI's financial position shows a mixed picture with balance sheet growth but worsening profitability. Current assets expanded meaningfully to $10.1M while stockholders' equity grew to $12.3M, indicating some operational scaling. However, gross profit declined substantially to $3.4M and net losses nearly doubled, while operating cash flow remained deeply negative at -$3.5M, signaling persistent operational inefficiencies despite the strategic pivot.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-95.8%
-$3.0M-$5.8M

Net income declined 95.8% — review whether driven by operations, interest costs, or non-recurring items.

Gross Profit
P&L
-41.3%
$5.8M$3.4M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Current Assets
Balance Sheet
+41.3%
$7.1M$10.1M

Current assets grew 41.3% — improving short-term liquidity or inventory/receivables build.

Operating Cash Flow
Cash Flow
-32.2%
-$2.7M-$3.5M

Operating cash flow fell 32.2% — earnings quality concerns; investigate working capital changes and non-cash items.

Current Liabilities
Balance Sheet
+25.4%
$4.9M$6.2M

Current liabilities rose 25.4% — increased short-term obligations, watch current ratio.

Inventory
Balance Sheet
+24.2%
$2.9M$3.6M

Inventory built 24.2% — monitor whether demand supports this build or if write-downs may follow.

Accounts Receivable
Balance Sheet
+22.3%
$3.5M$4.3M

Receivables grew 22.3% — monitor days sales outstanding for collection efficiency.

Stockholders Equity
Balance Sheet
+21.8%
$10.1M$12.3M

Equity base grew 21.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

R&D Expense
P&L
+17.9%
$982K$1.2M

R&D investment increased 17.9% — signals commitment to future product development, though near-term margin impact.

Total Assets
Balance Sheet
+17%
$16.9M$19.8M

Asset base grew 17% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2025-09-29
PRIOR — 2024-09-30
ADDED
Overview We have been a developer and manufacturer of advanced optical instruments since 1982, and we operate primarily in two key market segments: medical devices and advanced defense/aerospace products.
Within our proprietary optical and imaging technology, our unique custom designs, expert manufacturing capabilities, and advanced engineering and development capabilities have generated traditional endoscopes and endocouplers, digital imaging endoscopes using CMOS sensor technology, some designed and manufactured for single-use, as well as other, more advanced, custom imaging and illumination products for our customers use in minimally invasive surgical procedures.
We also apply our unique technologies to applications in the Defense / Aerospace markets including applications supporting satellite network communications.
To support these two critical market categories, our business operations are conducted in four areas: systems manufacturing, engineering and product development, Ross Optical components and assemblies, and our micro-optics laboratory.
Our systems manufacturing operations assemble and manufacture components and systems for both medical device and advanced aerospace customers who choose to outsource these services based on our ability to handle high complexity components, specific optical technologies, micro-optical assemblies and other advanced manufacturing challenges.
+7 more — sign up free →
REMOVED
Overview We have been a developer and manufacturer of advanced optical instruments since 1982.
Our proprietary medical instrumentation line, unique custom design and manufacturing capabilities, and expert engineering and development has generated traditional proprietary endoscopes and endocouplers as well as other custom imaging and illumination products for our customers use in minimally invasive surgical procedures.
Effective October 1, 2021, we acquired the operating assets of Lighthouse Imaging, LLC of Windham, Maine.
Our Lighthouse Imaging division supplements our operations as a manufacturer of advanced optical imaging systems and accessories and has provided further expertise in electrical engineering and development of end-to-end medical visualization devices.
Product development competencies at Lighthouse Imaging include Systems, Optical, Mechanical, Electrical and Process Development Engineering.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →